Cytogenetic findings in Wilms' tumour: A single institute study

Pathology

Volumn 42, Issue 7, 2010, Pages 643-649

  Mdzin, Reena ^a   Murch, Ashleigh ^a,b   Charles, Adrian ^a,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b KING EDWARD MEMORIAL HOSPITAL   (Australia)

^c PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

Author keywords

Cytogenetics; Kidney; Paediatrics; Wilms' tumour

Indexed keywords

EID: 78649262504     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.3109/00313025.2010.522171     Document Type: Article

References (50)

1. Breslow N, Olshan A, Beckwith JB, et al. Epidemiology of Wilms tumor. Med Pediatr Oncol 1993;21:172-81.
2. Kaneko Y, Egues MC, Rowley JD. Interstitial deletion of short arm of chromosome 11 limited to Wilms' tumor cells in a patient without aniridia. Cancer Res 1981;41:4577-8.
3. Mitelman F, Johansson B, Mertens FE, editors. Mitelman Database of Chromosome Aberrations in Cancer 2009. http://cgap. nci.nih.gov/Chromosomes/ Mitelman.
4. Gow KW, Murphy JJ. Cytogenetic and histologic findings in Wilms' tumor. J Pediatr Surg 2002;37:823-7.
5. Slater RM, Mannens MM. Cytogenetics and molecular genetics of Wilms' tumor of childhood. Cancer Genet Cytogenet 1992;61:111-21.
6. Knudson A. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68:820-3.
7. Strong LC. The two-hit model for Wilms' tumor: where are we 30 years later? Genes Chromosomes Cancer 2003;38:294-9.
8. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990;60:509-20.
9. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA. Homozygous deletion in Wilms tumors of a zinc-finger gene identified by chromosome jumping. Nature 1990;343:774-8.
10. Schumacher V, Schuhen S, Sonner S, et al. Two molecular subgroups of Wilms' tumors with or without WT1 mutations. Clin Cancer Res 2003;9:2005-14.
11. Ravenel JD, Broman KW, Perlman EJ, et al. Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor. J Natl Cancer Inst 2001;93:1698.
12. Fukuzawa R, Breslow NE, Morison IM, et al. Epigenetic differences between Wilms' tumours in white and east-Asian children. Lancet 2004;363:446-51.
13. Beckwith JB, Kiviat NB, Bonadio JF. Nephrogenic rests, nephroblastomatosis and the pathogenesis of Wilms' tumor. Pediatr Pathol 1990;10:1-36.
14. Fukuzawa R, Heathcott RW, More HE, Reeve AE. Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies. J Clin Pathol 2007;60:1013-6.
15. Park S, Bernard A, Bove KE, et al. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms tumour. Nat Genet 1993;5:363-7.
16. Charles AK, Brown KW, Berry PJ. Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development. Am J Pathol 1998;153:991-1000.
17. Cui H, Hedborg F, He L, et al. Inactivation of H19, an imprinted and putative tumor repressor gene, is a preneoplastic event during Wilms' tumorigenesis. Cancer Res 1997;57:4469-73.
18. Perlman EJ. Pediatric Renal tumors: practical updates for the pathologist. Pediatr Devel Pathol 2005;320:320-38.
19. Pandis N, Heim S, Bardi G, Limon J, Mandahl N, Mitelman F. Improved technique for short-term culture and cytogenetic analysis of human breast cancer. Genes Chromosomes Cancer 1992;5:14-20.
20. Mitelman F, editor. ISCN 1995: An International System For Human Cytogenetic Nomenclature (1995): Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature, Memphis, Tennessee, USA, October 9-13, 1994. Basel: Karger, 1995.
21. Shaffer LG, Tommerup N, editors. ISCN 2005: An International System for Human Cytogenetic Nomenclature. Basel: Karger, 2005.
22. Maiti S, Alam R, Amos CI, Huff V. Frequent association of betacatenin and WT1 mutations in Wilms tumors. Cancer Res 2000;60:6288-92.
23. Fukuzawa R, Heathcott RW, Sano M, Morison IM, Yun K, Reeve AE. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway. Pediatr Dev Pathol 2004;7:125-37.
24. Bardeesy N, Falkoff D, Petruzzi MJ, et al. Anaplastic Wilms' tumor, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet 1994;7:91-7.
25. Rivera MN, Kim WJ, Wells J, et al. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 2007;315:642-5.
26. Fukuzawa R, Anaka MR, Weeks RJ, Morison IM, Reeve AE. Canonical WNT signalling determines lineage specificity in Wilms tumour. Oncogene 2009;28:1063-75.
27. Rapley EA, Barfoot R, Bonaiti-Pellie C, et al. Evidence for susceptibility genes to familial Wilms tumour in addition to WT1, FWT1 and FWT2. Br J Cancer 2000;83:177-83.
28. Beckwith JB. Nephrogenic rests and the pathogenesis of Wilms tumor: developmental and clinical considerations. Am J Med Genet 1998;79:268-73.
29. Bown N, Cotterill SJ, Roberts P, et al. Cytogenetic abnormalities and clinical outcome in Wilms tumor: a study by the UK Cancer Cytogenetics Group and the UK Children's Cancer Study Group. Med Pediatr Oncol 2002;38:11-21.
30. Ehrlich M, Hopkins NE, Jiang G, et al. Satellite DNA hypomethylation in karyotyped Wilms tumors. Cancer Genet Cytogenet 2003;141:97-105.
31. Sheng WW, Soukup S, Bove K, Gotwals B, Lampkin B. Chromosome analysis of 31 Wilms' tumors. Cancer Res 1990;50:2786-93.
32. Dolan M, Mascotti K. Cytogenetically unrelated clones in different histologic components of a Wilms tumor. Cancer Genet Cytogenet 2005;159:63-8.
33. Dome JS, Coppes MJ. Recent advances in Wilms tumor genetics. Curr Opinion Pediatr 2002;14:5-11.
34. Grundy PE, Telzerow PE, Breslow N, Moksness J, Huff V, Paterson MC. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome. Cancer Res 1994;54:2331-3.
35. Klamt B, Schulze M, Thate C, et al. Allele loss in Wilms tumors of chromosome arms 11q, 16q, and 22q correlate with clinicopathological parameters. Genes Chromosomes Cancer 1998;22:287-94.
36. Wittmann S, Zirn B, Alkassar M, Ambros P, Graf N, Gessler M. Loss of 11q and 16q in Wilms tumors is associated with anaplasia, tumor recurrence, and poor prognosis. Genes Chromosomes and Cancer 2007;46:163-70.
37. Hing S, Lu YJ, Summersgill B, et al. Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors. Am J Pathol 2001;158:393-8.
38. Rassekh SR, Chan S, Harvard C, Dix D, Qiao Y, Rajcan-Separovic E. Screening for submicroscopic chromosomal rearrangements in Wilms tumor using whole-genome microarrays. Cancer Genet Cytogenet 2008;182:84-94.
39. Kaneko Y, Homma C, Maseki N, Sakurai M, Hata J. Correlation of chromosome abnormalities with histological and clinical features in Wilms' and other childhood renal tumors. Cancer Res 1991;51:5937-42.
40. Betts DR, Koesters R, Pluss HJ, Niggli FK. Routine karyotyping in Wilms tumor. Cancer Genet Cytogenet 1997;96:151-6.
41. Sandoval C, Ozkaynak MF, Tugal O, Jayabose S. Hyperdiploidy in a case of favorable histology Wilms tumor. Cancer Genet Cytogenet 2001;127:89-90.
42. Shearer PD, Valentine MB, Grundy P, et al. Hemizygous deletions of chromosome band 16q24 in Wilms tumor: detection by fluorescence in situ hybridization. Cancer Genet Cytogenet 1999;115:100-5.
43. Hastie ND. The genetics of Wilms' tumor-a case of disrupted development. Ann Rev Genet 1994;28:523-58.
44. Huff V. Wilms tumor genetics. Am J Med Genet 1998;79:260-7.
45. Little MH, Clarke J, Byrne J, Dunn R, Smith PJ. Allelic loss on chromosome 11p is a less frequent event in bilateral than in unilateral Wilms' tumours. Eur J Cancer 1992;28 A: 1876-80.
46. Tomlinson GS, Cole CH, Smith NM. Bilateral Wilms' tumor: a clinicopathologic review. Pathology 1999;31:12-6.
47. Nakadate H, Yokomori K, Watanabe N, et al. Mutations/deletions of the WT1 gene, loss of heterozygosity on chromosome arms 11p and 11q, chromosome ploidy and histology in Wilms' tumors in Japan. Int J Cancer 2001;94:396-400.
48. Stock C, Ambros IM, Lion T, et al. Genetic changes of two Wilms tumors with anaplasia and a review of the literature suggesting a marker profile for therapy resistance. Cancer Genet Cytogenet 2002;135:128-38.
49. Vujanic GM, Charles AK. Renal tumours of childhood: an update. Pathology 2008;40:217-27.
50. de Chadarevian JP, Punnett HH, Billmire DF, Tomczak EZ. Hyperdiploidy and trisomy 12 in the cystic partially differentiated nephroblastoma. Hum Pathol 1996;27:980-1.